methotrexate

Summary

Summary: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Top Publications

  1. pmc Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
    G Jones
    Menzies Research Institute, University of Tasmania, Hobart, TAS 7001, Australia
    Ann Rheum Dis 69:88-96. 2010
  2. pmc Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
    Maxime Dougados
    Department of Rheumatology, Cochin Hospital, Paris, France
    Ann Rheum Dis 72:43-50. 2013
  3. pmc Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    E C Keystone
    University of Toronto and Mount Sinai Hospital, Ontario, Canada
    Ann Rheum Dis 68:789-96. 2009
  4. pmc A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial
    Larry W Moreland
    University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Arthritis Rheum 64:2824-35. 2012
  5. ncbi Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
    Joel M Kremer
    Albany Medical College and Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 63:609-21. 2011
  6. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
  7. ncbi Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial
    Marije F Bakker
    Department of Rheumatology and Clinical Immunology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, and Diakonessenhuis, Utrecht, The Netherlands
    Ann Intern Med 156:329-39. 2012
  8. ncbi Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Roy Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 64:617-29. 2012
  9. ncbi Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
    Desiree van der Heijde
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 65:559-70. 2013
  10. pmc Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
    Arthur Kavanaugh
    UCSD, UCSD, Rheumatology, Allergy, Immunology, La Jolla, CA, USA
    Ann Rheum Dis 72:64-71. 2013

Detail Information

Publications377 found, 100 shown here

  1. pmc Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
    G Jones
    Menzies Research Institute, University of Tasmania, Hobart, TAS 7001, Australia
    Ann Rheum Dis 69:88-96. 2010
    ..The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis...
  2. pmc Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
    Maxime Dougados
    Department of Rheumatology, Cochin Hospital, Paris, France
    Ann Rheum Dis 72:43-50. 2013
    In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy.
  3. pmc Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    E C Keystone
    University of Toronto and Mount Sinai Hospital, Ontario, Canada
    Ann Rheum Dis 68:789-96. 2009
    The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy.
  4. pmc A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial
    Larry W Moreland
    University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Arthritis Rheum 64:2824-35. 2012
    ..2 at week 24) to methotrexate (MTX) monotherapy, and to assess whether combination therapy with MTX plus etanercept is superior to the ..
  5. ncbi Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
    Joel M Kremer
    Albany Medical College and Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 63:609-21. 2011
    To assess the efficacy and safety of tocilizumab plus methotrexate (MTX) versus MTX alone in preventing structural joint damage and improving physical function and disease activity in patients with moderate-to-severe rheumatoid arthritis ..
  6. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
    Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium.
  7. ncbi Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial
    Marije F Bakker
    Department of Rheumatology and Clinical Immunology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, and Diakonessenhuis, Utrecht, The Netherlands
    Ann Intern Med 156:329-39. 2012
    ..Treatment strategies for tight control of early rheumatoid arthritis (RA) are highly effective but can be improved...
  8. ncbi Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Roy Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 64:617-29. 2012
    ....
  9. ncbi Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
    Desiree van der Heijde
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 65:559-70. 2013
    ..24-month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX). Data from a planned 12-month interim analysis are reported.
  10. pmc Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
    Arthur Kavanaugh
    UCSD, UCSD, Rheumatology, Allergy, Immunology, La Jolla, CA, USA
    Ann Rheum Dis 72:64-71. 2013
    To assess the efficacy and safety of adalimumab plus methotrexate (ADA+MTX) compared with methotrexate monotherapy in achieving stable low disease activity (LDA; disease activity score (DAS28(CRP)) <3...
  11. ncbi A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
    P Mease
    Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 71:1183-9. 2012
    ..Interleukin 6 (IL-6) plays a key role in the inflammatory cascade in rheumatoid arthritis. BMS945429 is a humanised, monoclonal antibody that potently binds IL-6...
  12. ncbi Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
    Gerd R Burmester
    Charite University Medicine Berlin, Berlin, Germany
    Lancet 381:451-60. 2013
    ..We investigated the effectiveness of tofacitinib (CP-690,550), a novel oral Janus kinase inhibitor, as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis...
  13. pmc Methotrexate for ocular inflammatory diseases
    Sapna Gangaputra
    Department of Ophthalmology, The Fundus Photograph Reading Center, University of Wisconsin, Madison, Wisconsin, USA
    Ophthalmology 116:2188-98.e1. 2009
    To evaluate the outcome of treatment with methotrexate for noninfectious ocular inflammation.
  14. ncbi Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate
    Kyoung Jin Sohn
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    J Natl Cancer Inst 96:134-44. 2004
    ..We hypothesized that this polymorphism may modulate the cytotoxic effect of 5-fluorouracil (5FU) and methotrexate (MTX), two commonly used chemotherapeutic agents for colon and breast cancers, because the modes of action of ..
  15. pmc Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    M Schiff
    Denver Arthritis Clinic, 200 Spruce Street 100, Denver, CO 80230, USA
    Ann Rheum Dis 67:1096-103. 2008
    ..The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197...
  16. pmc Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
    R Westhovens
    UZ Gasthuisberg, Department of Rheumatology, B 3000 Leuven, Belgium
    Ann Rheum Dis 68:1870-7. 2009
    To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) and poor prognostic factors.
  17. ncbi A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    Joel M Kremer
    Albany Medical College, Albany, New York 12206, USA
    Arthritis Rheum 64:970-81. 2012
    ..of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy.
  18. ncbi Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester
    Faruk Oktem
    Department of Pediatric Nephrology, School of Medicine, Suleyman Demirel University, 32260 Isparta, Turkey
    Toxicol Ind Health 22:241-7. 2006
    The exact mechanisms of methotrexate-induced renal toxicity have not yet been determined. However, several hypotheses have been put forward, including oxidative stress...
  19. pmc Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
    C Salliot
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 68:1100-4. 2009
    To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA).
  20. ncbi Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis
    Lilian H D van Tuyl
    VU University Medical Center, Department of Rheumatology, ZH 3A 56, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Rheum Dis 69:807-12. 2010
    ..This study evaluates survival, comorbidities and joint damage in the original COBRA trial cohort...
  21. ncbi Therapies for active rheumatoid arthritis after methotrexate failure
    JAMES R O'DELL
    Veterans Affairs VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE 68105, USA
    N Engl J Med 369:307-18. 2013
    ..of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis.
  22. ncbi Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-bli
    Paul Emery
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, corrected Leeds, UK
    Arthritis Rheum 60:2272-83. 2009
    To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis (RA).
  23. pmc Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
    Yoshiya Tanaka
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu City, Japan
    Ann Rheum Dis 71:817-24. 2012
    To assess the efficacy and safety of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA).
  24. ncbi Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]
    J Simon W Stewart
    Charing Cross Hospital, London, UK
    J Clin Oncol 27:1864-71. 2009
    To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or standard methotrexate.
  25. ncbi Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
    P P Tak
    Division of Clinical Immunology and Rheumatology, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    Ann Rheum Dis 70:39-46. 2011
    ..The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX.
  26. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
    To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC).
  27. pmc Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, 1367 Washington Ave, Albany, NY 12206, USA
    Ann Rheum Dis 70:1826-30. 2011
    To evaluate abatacept treatment over 3 years in patients with rheumatoid arthritis (RA) refractory to methotrexate (MTX).
  28. ncbi Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
    ..ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with ..
  29. ncbi In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
    Hamed Rezaei
    Unit of Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:186-91. 2012
    To investigate the 2-year clinical and radiological outcomes of patients with early rheumatoid arthritis (RA; symptom duration <1 year) who had initially responded well to methotrexate monotherapy.
  30. ncbi A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach
    Susanne Schmitz
    Department of Statistics, Trinity College Dublin, Ireland
    Ann Rheum Dis 71:225-30. 2012
    ..is to estimate the relative efficacy among licensed anti-TNFs in patients who have had an inadequate response to methotrexate (MTX). Different outcome measures are used to highlight the advantages of continuous measures in such analyses.
  31. ncbi High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
    M J Glantz
    Department of Medicine, Brown University School of Medicine, Providence, RI, USA
    J Clin Oncol 16:1561-7. 1998
    ..t. therapy alone. We present our experience, which includes CSF and serum pharmacokinetic data, on the use of high-dose (HD) intravenous (i.v.) methotrexate (MTX) as the sole treatment for neoplastic meningitis.
  32. ncbi A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors
    M J Glantz
    Department of Medicine, Brown University School of Medicine, Providence, Rhode Island 02860, USA
    Clin Cancer Res 5:3394-402. 1999
    ..We conducted a randomized, controlled trial of DepoCyt versus methotrexate in patients with solid tumor neoplastic meningitis...
  33. ncbi Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients
    S A Owen
    Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK
    Pharmacogenomics J 13:227-34. 2013
    We investigated the effect of single-nucleotide polymorphisms (SNPs) spanning 10 methotrexate (MTX) pathway genes, namely AMPD1, ATIC, DHFR, FPGS, GGH, ITPA, MTHFD1, SHMT1, SLC19A1 (RFC) and TYMS on the outcome of MTX treatment in a UK ..
  34. ncbi Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
    Dora Pascual-Salcedo
    Immunology Unit, Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
    Rheumatology (Oxford) 50:1445-52. 2011
    ..To analyse the clinical relevance of the production of anti-infliximab antibodies (anti-infliximab Abs) in patients with RA undergoing infliximab treatment over a prolonged period of time...
  35. pmc Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate
    M C Genovese
    Stanford University, Palo Alto, California 94304, USA
    Arthritis Rheum 63:2854-64. 2011
    ..To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept...
  36. pmc A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
    Gabrielle H Kingsley
    Department of Rheumatology, King s College London School of Medicine, King s College London, London SE5 9RJ, UK
    Rheumatology (Oxford) 51:1368-77. 2012
    ..MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our study was to test the value of MTX in the first large randomized placebo-controlled trial (RCT) in PsA...
  37. pmc Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
    J Smolen
    Department of Internal Medicine III, Medical University of Vienna and 2nd Department of Medicine, Hietzing Hospital, Austria
    Ann Rheum Dis 68:797-804. 2009
    ..Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor...
  38. ncbi Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report
    Hans Joachim Stemmler
    Medical Department III, Ludwig Maximilians University of Munich, Klinikum Grosshadern, Munich, Germany
    Anticancer Drugs 19:832-6. 2008
    ..We herewith report on a patient suffering from HER2 overexpressing MBC who received intrathecal methotrexate and trastuzumab for meningeal carcinomatosis...
  39. ncbi Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat
    Riejanne Seigers
    Department of Behavioral Physiology, University of Groningen, Kerklaan 30, 9750 AA Haren, The Netherlands
    Behav Brain Res 186:168-75. 2008
    b>Methotrexate (MTX) is a cytostatic agent widely used in combination with other agents as adjuvant chemotherapy for breast cancer and is associated with cognitive impairment as a long-term side effect in some cancer patients...
  40. pmc Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Effi
    P Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds corrected
    Ann Rheum Dis 69:1629-35. 2010
    This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment.
  41. pmc Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
    S Pyrhonen
    Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 71:587-91. 1995
    A phase III randomised study, comparing treatment with fluorouracil, epidoxorubicin and methotrexate (FEMTX) with the best supportive care, was conducted in patients with unresectable or metastatic gastric cancer...
  42. pmc IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    P Emery
    Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:1516-23. 2008
    ..The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy...
  43. ncbi Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
    J L Nam
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK
    Ann Rheum Dis 69:976-86. 2010
    ..To review the evidence for the efficacy and safety of biological agents in patients with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the European League Against Rheumatism (EULAR) Task Force...
  44. ncbi Understanding and managing methotrexate nephrotoxicity
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 CRC Room 1 5750, Bethesda, Maryland 20892 1101, USA
    Oncologist 11:694-703. 2006
    b>Methotrexate (MTX) is one of the most widely used anti-cancer agents, and administration of high-dose methotrexate (HDMTX) followed by leucovorin (LV) rescue is an important component in the treatment of a variety of childhood and adult ..
  45. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..drugs and/or intra-articular steroid injections, the use of disease-modifying antirheumatic drugs, particularly methotrexate, along with the biologic agents, are considered the standard of care in patients with more significant ..
  46. ncbi Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1
    Stefano Ferrari
    Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 30:2112-8. 2012
    We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity.
  47. pmc Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease
    Renata Micha
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Am J Cardiol 108:1362-70. 2011
    ..b>Methotrexate is a disease-modifying antirheumatic drug broadly used for the treatment of chronic inflammatory disorders...
  48. ncbi Underexpression of miR-224 in methotrexate resistant human colon cancer cells
    Núria Mencia
    Department of Biochemistry and Molecular Biology, School of Pharmacy, University of Barcelona, E 08028 Barcelona, Spain
    Biochem Pharmacol 82:1572-82. 2011
    ..These results revealed a role for miR-224 and its targets in MTX resistance in HT29 colon cancer cells...
  49. ncbi Attenuated Wnt/β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats
    Kristen R Georgiou
    Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia
    Bone 50:1223-33. 2012
    ..pathway in changes to bone marrow stromal and haematopoietic cell differentiation after chemotherapy with methotrexate (MTX), a commonly used antimetabolite. MTX treatment in rats (5 daily administrations at 0...
  50. ncbi Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden
    Lancet 379:1712-20. 2012
    ..agent gave an improved clinical outcome compared with the addition of conventional disease-modifying antirheumatic drugs in patients with methotrexate-refractory early rheumatoid arthritis. Here we report the 2 year follow-up assessment.
  51. ncbi Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis
    Thierry Dervieux
    Prometheus Laboratories, San Diego, California, USA
    Arthritis Rheum 50:2766-74. 2004
    b>Methotrexate (MTX) enters cells through the reduced folate carrier (RFC-1) and exerts part of its effects through polyglutamation to MTX polyglutamates (MTXPGs) and inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide ..
  52. pmc Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis
    Carol A Wallace
    Seattle Children s Hospital, Seattle, WA, USA
    Arthritis Rheum 64:2012-21. 2012
    ..To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)-positive or RF-negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months...
  53. ncbi Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells
    Nathan Kohler
    Department of Materials Science and Engineering, University of Washington, Seattle, Washington 98195 2120, USA
    Langmuir 21:8858-64. 2005
    ..The conjugate is made of iron oxide nanoparticles covalently bound with methotrexate (MTX), a chemotherapeutic drug that can target many cancer cells whose surfaces are overexpressed by folate ..
  54. ncbi The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester
    Ertugrul Uzar
    School of Medicine Department of Neurology, Suleyman Demirel University, Isparta, Turkey
    Mol Cell Biochem 291:63-8. 2006
    b>Methotrexate (MTX), a folic acid antagonist, is widely used as a cytotoxic chemotherapeutic agent. MTX-associated neurotoxicity is an important clinical problem...
  55. ncbi Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits
    Adriana Bulgarelli
    Lipid Metabolism Laboratory, Heart Institute of the Medical School Hospital InCor, A C Camargo Hospital, Sao Paulo, Sao Paulo, Brazil
    J Cardiovasc Pharmacol 59:308-14. 2012
    ..A decrease in the number of cardiovascular events in patients with rheumatoid arthritis or psoriasis treated with methotrexate (MTX) has been observed in the literature...
  56. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment.
  57. ncbi Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
    Paul Emery
    Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 71:989-92. 2012
    ..Treatment response in VERA and early rheumatoid arthritis (ERA; >4 months to 2 years) with combination etanercept+methotrexate (ETN+MTX) or MTX monotherapy was compared.
  58. ncbi Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study
    Hideto Kameda
    Japan Biological Agent Integrated Consortium JBASIC, Keio University, Tokyo, Japan
    J Rheumatol 38:1585-92. 2011
    The aim of the Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan (JESMR) study is to compare the efficacy of continuation versus discontinuation of methotrexate (MTX) when starting ..
  59. ncbi Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma
    Hiroyuki Imanishi
    Department of Pediatrics, Kobe University Graduate School of Medicine, 7 5 1, Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    J Hum Genet 52:166-71. 2007
    b>Methotrexate is administered in high doses to treat childhood acute lymphoblastic leukemia and malignant lymphoma. Hepatotoxicity and bone marrow suppression often limit its use, however...
  60. ncbi Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema
    Simon R J Taylor
    Department of Clinical Ophthalmology, UCL Institute of Ophthalmology, Moorfields Eye Hospital, London, UK
    Ophthalmology 116:797-801. 2009
    A pilot study to evaluate the use of intravitreal methotrexate (MTX) for the treatment of uveitis and uveitic cystoid macular edema (CME).
  61. ncbi Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate
    Katia Varani
    University of Ferrara, Ferrara, Italy
    Arthritis Rheum 60:2880-91. 2009
    ..and neutrophils from patients with early rheumatoid arthritis (ERA) as well as from RA patients treated with methotrexate (MTX) or anti-tumor necrosis factor alpha (anti-TNFalpha), as compared with those in age-matched healthy ..
  62. pmc Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis
    Anne Hinks
    Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
    Ann Rheum Dis 70:1395-400. 2011
    b>Methotrexate (MTX) is the mainstay treatment for juvenile idiopathic arthritis (JIA), however approximately 30% of children will fail to respond to the drug...
  63. pmc Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways
    Mark J Crabtree
    Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    J Biol Chem 284:28128-36. 2009
    ..Pharmacological inhibition of DHFR activity by methotrexate or genetic knockdown of DHFR protein by RNA interference reduced intracellular BH4 and increased BH2 levels ..
  64. ncbi Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis
    Philip G Conaghan
    University of Leeds and Leeds General Infirmary, Leeds, UK
    Arthritis Rheum 48:64-71. 2003
    ..To simultaneously image bone and synovium in the individual joints characteristically involved in early rheumatoid arthritis (RA)...
  65. ncbi The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients
    Cai Yue
    Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China
    Rheumatol Int 30:1553-7. 2010
    ..In conclusion, adalimumab and MTX treatment down regulates peripheral Th17 cells and serum IL-6 level in RA patients. Baseline Th17 level negatively predicts the effect of adalimumb/MTX treatment...
  66. ncbi Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity
    J S Johansen
    Department of Rheumatology, Hvidovre Hospital, Denmark
    Rheumatology (Oxford) 38:618-26. 1999
    ..Studies have shown that YKL-40 is an autoantigen in rheumatoid arthritis (RA). We evaluated whether serum YKL-40 was related to disease activity in patients with RA...
  67. ncbi Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium
    Robert Dreicer
    Department of Hematology Oncology and Urologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 100:1639-45. 2004
    The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) were compared in patients with advanced urothelial carcinoma.
  68. ncbi A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate
    Nicolino Ruperto
    IRCCS G Gaslini, University of Genoa, Genoa, Italy
    Arthritis Rheum 50:2191-201. 2004
    To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m(2)/week) versus a higher dosage (30 mg/m(2)/week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed ..
  69. pmc Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
    Moetaza M Soliman
    Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, The University of Manchester, Oxford Road, Manchester M13 9PT, UK
    Ann Rheum Dis 70:583-9. 2011
    ..To evaluate the effect of different concomitant disease modifying antirheumatic drugs (DMARDs) on the persistence with antitumour necrosis factor (anti-TNF) therapies in patients with rheumatoid arthritis (RA)...
  70. ncbi Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery
    Nathan Kohler
    Department of Materials Science and Engineering, University of Washington, Seattle, WA98195, USA
    Small 2:785-92. 2006
    We report the development of a biostable methotrexate-immobilized iron oxide nanoparticle drug carrier that may potentially be used for real-time monitoring of drug delivery through magnetic resonance imaging...
  71. ncbi The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
    Paul Emery
    University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK
    Arthritis Rheum 63:1200-10. 2011
    ..To evaluate the effects of golimumab on radiographic progression in patients with rheumatoid arthritis (RA)...
  72. pmc Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
    Geertje M Bartelds
    Jan van Breemen Institute, 1056 AB Amsterdam, The Netherlands
    Ann Rheum Dis 66:921-6. 2007
    ..A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that patients develop anti-adalimumab antibodies...
  73. ncbi A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis
    Nicolino Ruperto
    IRCCS, Istituto G Gaslini, Genoa, Italy
    Arthritis Rheum 56:3096-106. 2007
    ..To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA)...
  74. pmc Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
    William Stohl
    Division of Rheumatology, Los Angeles County and University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Ann Rheum Dis 71:1289-96. 2012
    To determine the efficacy and safety of ocrelizumab (OCR) with methotrexate (MTX) in MTX-naive rheumatoid arthritis (RA) patients.
  75. ncbi Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis
    Jean Francis Maillefert
    INSERM U887, Department of Rheumatology, Hopital General, Dijon University Hospital, University of Burgundy, 3, rue du Fb Raines, 21078 Dijon, France
    Joint Bone Spine 77:558-63. 2010
    ..To investigate potential predictors of response to conventional DMARDs in RA...
  76. pmc Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
    Marije F Bakker
    Correspondence to Marije F Bakker, UMC Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht PO BOX 85500, The Netherlands
    Ann Rheum Dis 71:1692-7. 2012
    ....
  77. ncbi Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis
    Thierry Dervieux
    Exagen Diagnostics, Inc, Albuquerque, New Mexico, USA
    Pharmacogenet Genomics 22:1-9. 2012
    The contribution of low-penetrance single nucleotide polymorphisms to methotrexate efficacy in rheumatoid arthritis (RA) is inconsistent between studies...
  78. ncbi Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis
    Tomoyuki Imagawa
    Department of Pediatrics, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama, Kanagawa 236 0004, Japan
    Mod Rheumatol 22:109-15. 2012
    ..Nineteen patients intractable to conventional methotrexate therapy were enrolled. Seventeen patients had polyarticular-onset pJIA; two had oligoarticular-onset pJIA...
  79. pmc Immunomodulatory drugs regulate HMGB1 release from activated human monocytes
    Hanna Schierbeck
    Department of Women s and Children s Health, Pediatric Unit, Karolinska Institutet, Stockholm, Sweden
    Mol Med 16:343-51. 2010
    ..were assessed in cultures supplemented with dexamethasone, cortisone, chloroquine, gold sodium thiomalate, methotrexate, colchicine, etanercept or anakinra...
  80. ncbi Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia
    Elixabet Lopez-Lopez
    Department of Genetics, Physic Anthropology and Animal Physiology, University of the Basque Country, Leioa, Spain
    Pediatr Blood Cancer 57:612-9. 2011
    b>Methotrexate (MTX) is an important component of the therapy for childhood acute lymphoblastic leukemia. Treatment with high-dose MTX often causes toxicity, recommending a dose reduction and/or cessation of treatment...
  81. pmc International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial
    Gareth Griffiths
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Clin Oncol 29:2171-7. 2011
    ..results of the international multicenter randomized trial that investigated the use of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) chemotherapy in patients with muscle-invasive urothelial cancer of the bladder treated ..
  82. pmc A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL)
    Michael A Pulsipher
    Division of Hematology Blood and Marrow Transplant, Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84132 2408, USA
    Br J Haematol 147:691-9. 2009
    ..We hypothesized that the addition of sirolimus to a tacrolimus/methotrexate graft-versus-host disease (GVHD) prophylaxis regimen would decrease relapse after haematopoietic stem cell ..
  83. ncbi Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma
    Dhong Hyun Lee
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Cancer Lett 306:161-70. 2011
    ..the use of cucurbitacin B, a plant-derived tetracyclic triterpenoid, as a single agent or in combination with methotrexate (MTX) for human osteosarcoma (OS) treatment...
  84. ncbi Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:383-8. 2005
    ..b>Methotrexate, an antiproliferative graft-versus-host disease (GVHD) prophylaxis agent, impairs mucosal regeneration and ..
  85. ncbi Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes
    Robert Landewe
    University Hospital Maastricht, Maastricht, The Netherlands
    Arthritis Rheum 54:3119-25. 2006
    ..disease activity and radiographic progression of joint destruction in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX), those treated with etanercept, and those treated with the combination of MTX plus etanercept.
  86. ncbi Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growt
    Nan Soon Wong
    Sunnybrook Odette Cancer Centre, Ontario Clinical Oncology Group, University of Toronto, 2075 Bayview Ave, Toronto M4N3M5, Ontario, Canada
    J Clin Oncol 28:723-30. 2010
    ..to evaluate the safety and activity of adding dalteparin and prednisone to metronomic cyclophosphamide and methotrexate in women with measurable metastatic breast cancer (MBC)...
  87. pmc Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
    P L C M van Riel
    Radboud University Nijmegen Medical Centre, Department of Rheumatology, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
    Ann Rheum Dis 65:1478-83. 2006
    To evaluate the efficacy and safety of etanercept (ETN) monotherapy compared with combination ETN and methotrexate (MTX) treatment in patients with rheumatoid arthritis who had an inadequate response to MTX monotherapy...
  88. pmc miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit
    Bo Song
    Translational Research Laboratory, Department of Pathology, Stony Brook University Medical Center, Stony Brook, New York 11794 8691, USA
    Clin Cancer Res 14:8080-6. 2008
    ..The purpose of this study is to investigate the molecular mechanism of miR-192 in colon cancer...
  89. ncbi Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis
    Paul Emery
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    J Rheumatol 36:1429-41. 2009
    To determine the relationship between radiographic progression and clinical response for adalimumab plus methotrexate (MTX) versus either monotherapy in patients with early rheumatoid arthritis (RA) in the PREMIER study.
  90. ncbi Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort
    Mohammed Z Cader
    Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
    Ann Rheum Dis 70:949-55. 2011
    ..This study therefore assesses the performance of these new criteria in patients with early synovitis...
  91. ncbi Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99
    Silvia R Brandalise
    Universidade Estadual de Campinas, Rua Vital Brasil, 100 Cx Postal 6141, Campinas, Sao Paulo 13083 970, Brazil
    J Clin Oncol 28:1911-8. 2010
    ..acute lymphoblastic leukemia (ALL) assigned to receive either continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX) or intermittent 6-MP with intermediate-dose MTX, as maintenance treatment...
  92. ncbi Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis
    Thierry Dervieux
    Cypress Bioscience, San Diego, California 92121, USA
    Pharmacogenet Genomics 19:935-44. 2009
    ..nucleotide polymorphism has emerged as pivotal to predict the lack of efficacy and dose-limiting toxicities to methotrexate (MTX), we evaluated the contribution of gene-gene interactions to the effects of this prodrug in rheumatoid ..
  93. pmc Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH)
    Celina Alves
    Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Ann Rheum Dis 70:1645-7. 2011
    ..An ACR/EULAR task force released new criteria to classify rheumatoid arthritis at an early stage. This study evaluates the diagnostic performance of these criteria and algorithms by van der Helm and Visser in REACH...
  94. ncbi Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis
    N Nakashima-Matsushita
    Kagoshima University School of Medicine, Japan
    Arthritis Rheum 42:1609-16. 1999
    To investigate the expression of folate receptors (FR) and reduced folate carrier (RFC) and determine their relevance to methotrexate (MTX) transport in synovial mononuclear cells (SMC) from patients with rheumatoid arthritis (RA).
  95. pmc Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival
    Alessia Ongaro
    Department of Morphology and Embryology, Section of Histology, University of Ferrara, Via Fossato di Mortara 64 b, 44100 Ferrara, Italy
    Haematologica 94:1391-8. 2009
    The antifolate agent methotrexate is an important component of maintenance therapy in acute lymphoblastic leukemia, although methotrexate-related toxicity is often a reason for interruption of chemotherapy...
  96. ncbi Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria
    Karin Britsemmer
    Department of Rheumatology, Jan van Breemen Research Institute I Reade, Amsterdam, The Netherlands
    Ann Rheum Dis 70:1468-70. 2011
    ..Recently, an American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) collaboration developed new classification criteria for rheumatoid arthritis (RA)...
  97. ncbi Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups
    Stefano Ferrari
    Chemotherapy Division of Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Via C Pupilli 1, 40136 Bologna, Italy
    J Clin Oncol 23:8845-52. 2005
    ..To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity...
  98. ncbi Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study
    Paul Emery
    University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, corrected Leeds, UK
    Arthritis Rheum 62:674-82. 2010
    To evaluate how continuation of and alterations to initial year 1 combination etanercept-methotrexate (MTX) therapy and MTX monotherapy regimens affect long-term remission and radiographic progression in early, active rheumatoid arthritis.
  99. ncbi Methotrexate--how does it really work?
    Edwin S L Chan
    Department of Medicine, New York University School of Medicine, 550 First Avenue, NBV16N1, New York, NY 10016, USA
    Nat Rev Rheumatol 6:175-8. 2010
    b>Methotrexate remains a cornerstone in the treatment of rheumatoid arthritis and other rheumatic diseases...
  100. ncbi Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production
    C C Huang
    Tzu Hui Institute of Technology, Pingtung, Taiwan, ROC
    Apoptosis 10:895-907. 2005
    b>Methotrexate (MTX), a folate antagonist, was developed for the treatment of malignancies, and is currently used in rheumatoid arthritis (RA) and other chronic inflammatory disorders...
  101. pmc Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986
    Maria De Santis
    Kaiser Franz Josef Hospital and Applied Cancer Research Institution for Translational Research, Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria
    J Clin Oncol 27:5634-9. 2009
    ..We report here the phase II results of the study...

Research Grants68

  1. Pharmacogenetics of Methotrexate Therapy in Arthritis
    ALEXANDER WHITEHEAD; Fiscal Year: 2006
    ..Low dose methotrexate (MTX) therapy is a mainstay for the long-term management of arthritis...
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema with Intravitreal Methotrexate Number: 11-EI-0107 Summary: Background: - Uveitis comprises of a group of diseases associated with inflammation ..
  3. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema with Intravitreal Methotrexate Number: 11-EI-0107 Summary: Background: - Uveitis comprises of a group of diseases associated with inflammation ..
  4. Serpin Modulation of Inflammatory Vasculitis; Potential for Immunomodulatory Ther
    ALEXANDRA ROSE LUCAS; Fiscal Year: 2010
    ..Other newer medical treatments such as TNF inhibitors and methotrexate have had only partial success in limited subsets of patients...
  5. Inhibition of IkK to treat lethal Graft-vs.-Host Disease
    Patrick Flood; Fiscal Year: 2009
    ..approaches to the prevention of GVHD are either a combination of S-phase active chemotherapy drugs such as methotrexate and a calcineuring inhibitor or in vivo methods of T cell depletion using antibodies such as Campath -1H...
  6. Molecular Mechanism of Immune Therapy for Bone Marrow Failures
    Pearlie K Epling-Burnette; Fiscal Year: 2013
    ..these syndromes are characterized by clinical improvement with immunosuppressive therapy (IST) such as low-dose methotrexate (MTX), low- dose cyclophosphamide (CY) or cyclosporine A (CyA) and, in the case of aplastic anemia and MDS, T ..
  7. Chemokine Decoy Receptor for Therapy of Autoimmune Arthritis
    Kanneganti Murthy; Fiscal Year: 2012
    ..provided by applicant): Current therapeutic approaches to rheumatoid arthritis ("RA") (corticosteroids, methotrexate, neutralization of TNF-?) rely upon broad-spectrum immunosuppression, an approach that is not uniformly ..
  8. A rational approach to liver toxicity monitoring in methotrexate users
    Gabriela Schmajuk; Fiscal Year: 2013
    ..and electronic health record data to develop a rational approach to drug toxicity monitoring using methotrexate, the first-line treatment for patients with inflammatory arthritis, as a model drug...
  9. Proteomic Identification of Actionable Biomarkers in Rheumatoid Arthritis
    William H Robinson; Fiscal Year: 2010
    ..g., methotrexate in concert with an anti-TNF agent) in order to slow and prevent joint damage...
  10. DECISION SUPPORT SYSTEM TO GUIDE PEDIATRIC PHARMACOTHERAPY
    JEFFREY SCOTT BARRETT; Fiscal Year: 2010
    ..Drug dashboard prototypes for methotrexate (chemotherapeutic agent) and tacrolimus (used to prevent organ rejection) are under development and will be ..
  11. Cell cycle checkpoint defects lead to chronic inflammation in RA
    Thomas M Aune; Fiscal Year: 2013
    ..b>Methotrexate, in cell models and in lymphocytes from subjects with rheumatoid arthritis, corrects expression levels of JNK2, ..
  12. Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD
    Leslie S Kean; Fiscal Year: 2013
    ....
  13. Functions of MRP2 and MRP3 in Drug Disposition
    James M Gallo; Fiscal Year: 2011
    ..MRP3, which is able to transport etoposide and methotrexate, is localized on the basolateral surfaces of gut enterocytes, and is induced at basolateral surfaces of ..
  14. Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008
    Richard J Barohn; Fiscal Year: 2012
    ..b>Methotrexate (MTX) is an analogue of folic acid and is an anti-metabolite and a potent inhibitor of dihydrofolate reductase, ..
  15. ALL therapy and developing brains: MRI measures, genetic factors and cognition
    Wilburn E Reddick; Fiscal Year: 2013
    ..We demonstrated that methotrexate exposure results in 1) white matter damage preferentially in the frontal lobes and 2) specific neurocognitive ..
  16. Proton-coupled folate/antifolate transport
    ISRAEL DAVID GOLDMAN; Fiscal Year: 2013
    ..1 is to characterize PCFT-mediated transport and its impact on the pharmacological activities of pemetrexed and methotrexate in vitro under conditions that simulate drug pharmacokinetics in clinical regimens and at pH's that ..
  17. Comparative Effectiveness of Biologics for Psoriasis
    Joel M Gelfand; Fiscal Year: 2010
    ..effectiveness of existing therapies for moderate to severe psoriasis such as phototherapy, acitretin, methotrexate, cyclosporine, alefacept, etanercept, adalimumab, infliximab, and ustekinumab...
  18. Cardiovascular Inflammation Reduction Trial (CIRT): DCC
    Robert J Glynn; Fiscal Year: 2013
    ..is to directly test the inflammatory hypothesis of atherothrombosis by evaluating whether or not low-dose methotrexate (LDM) will reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among patients ..
  19. Cardiovascular Inflammation Reduction Trial (CIRT)
    Paul M Ridker; Fiscal Year: 2013
    ..is to directly test the inflammatory hypothesis of atherothrombosis by evaluating whether or not low-dose methotrexate (LDM) will reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among patients ..
  20. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward A Neuwelt; Fiscal Year: 2012
    ..series of 174 patients with primary central nervous system lymphoma (PCNSL) treated up front with methotrexate based chemotherapy and BBBD, with a 40% progression free survival at 5 years...
  21. T Cell Signaling in Rheumatoid Arthritis
    Jorg J Goronzy; Fiscal Year: 2013
    ..In Specific Aim 3, we will determine whether existing standard (methotrexate, leflunomide or TNF inhibition) and newly emerging treatment approaches such as JAK3 inhibition are able to ..
  22. Childhood Leukemia: Oxidative Stress, Cognitive Changes &Academic Outcomes
    IDA MARIE MOORE; Fiscal Year: 2013
    ..Central nervous system (CNS) treatment with intrathecal and intravenous methotrexate is an essential part of ALL therapy because the brain is a sanctuary site for leukemia cells...
  23. Electronic Diary Assessment of Pain in Juvenile Arthritis
    Laura E Schanberg; Fiscal Year: 2010
    ..In spite of advances in medical therapy including the widespread use of methotrexate and biologic medications, pain persists as an unexpectedly common problem for children with JIA...
  24. Effector function of natural killer T (NKT) cells in sarcoidosis
    Laura L Koth; Fiscal Year: 2010
    ..g. systemic corticosteroids and methotrexate) are non-specific and have significant toxicities...
  25. Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leuke
    Craig A Mullen; Fiscal Year: 2010
    ..mechanisms of action: (a) imatinib (a tyrosine kinase inhibitor of the bcr-abl fusion protein);(b) pulsatile methotrexate (an antimetabolite);and (c) anti-CD20 monoclonal antibody...
  26. Immune mechanisms of CAM intervention in autoimmunity
    BRIAN CALVIN ASTRY; Fiscal Year: 2013
    ..a disease-modulating peptide of rat heat-shock protein (R465) or the conventionally used anti-arthritic drug, methotrexate. The results of this study would help significantly in establishing a reliable scientific basis for the use of ..
  27. Purine Synthesis Inhibitors with Selective Folate Receptor Tumor Transport
    Larry H Matherly; Fiscal Year: 2013
    ..Currently approved antitumor antifolates, methotrexate, pemetrexate, raltitrexed and pralatrexate, are all transported by the ubiquitous, reduced folate carrier (RFC) ..
  28. Psoriasis treatments, cardiovascular disease, and diabetes
    Lisa J Herrinton; Fiscal Year: 2013
    ..The drugs under study will include anti-TNF agents, methotrexate, oral retinoids and cyclosporine...
  29. NIAMS MULTIDISCIPLINARY CLINICAL RESEARCH CENTER
    Robert P Kimberly; Fiscal Year: 2012
    ..1, Genetic and Molecular Markers of Methotrexate Efficacy and Toxicity in Early RA (Arnett);No, 2, Ethnic Disparities in Total Joint Arthroplasty: Pain and ..
  30. Therapeutic Targeting of Novel Antifolates to Solid Tumors via Folate Receptor
    SHERMAINE KIMBERLY MITCHELL; Fiscal Year: 2013
    Antifolates such as methotrexate were originally developed as valuable chemotherapy agents to treat hematopoietic malignancies. More recently, newer antifolates were developed for treating solid tumors...
  31. Effects of chemotherapeutic agents on learning and memory in mice
    ELLEN ANN WALKER; Fiscal Year: 2013
    ..we will treat male and female mice with multiple doses of cyclophosphamide, doxorubicin, 5-fluorouracil, methotrexate, tamoxifen, and docetaxel at various time points to measure effects on acquisition, consolidation, retrieval, ..
  32. Risk-Informed Interventions in Community Pharmacy: Implementation and Evaluation
    Michael R Cohen; Fiscal Year: 2010
    ..detected when modeling the dispensing of four high-alert medications: waFOArin, fentanyl patches, methotrexate, and insulin...
  33. SNPs in Handling of Small Pox Antivirals and Other Drugs
    Sanjay Nigam; Fiscal Year: 2009
    At physiological pH, many drugs (eg. penicillins, NSAIDs, methotrexate, thiazides) exist as organic anions and are eliminated via the kidney proximal tubule through multispecific renal organic anion transporters (especially OAT1 and OAT3)...
  34. Mechanisms of Cytotoxicity and Radiosensitization for Antimetabolites
    Donna S Shewach; Fiscal Year: 2013
    ..function as radiosensitizers, such as hydroxyurea (ribonucleotide reductase inhibitor), and fluorodeoxyuridine, methotrexate and pemetrexed (thymidylate synthase inhibitors) to produce the first unifying hypothesis for antimetabolite ..
  35. KillerRed Assisted Mutagenesis to discover cancer drug resistance genes
    Daniel G Jay; Fiscal Year: 2013
    ..To develop and test KRAM, we will use it to identify genes that act in methotrexate resistance of chronic myelogenous leukemia (CML), a well-characterized process whose genes are known...
  36. Chemically Controlled Assembly of Therapuetic Protein Nanostrctures
    Carston R Wagner; Fiscal Year: 2010
    ..proteins that are able to self-assemble into bivalent, tetravalent or octavalent species in the presence of a methotrexate dimerizer coupled to a fluorophore or chelated radionuclides...
  37. Systemic cancer treatment and subsequent cognitive decline
    Francine Grodstein; Fiscal Year: 2013
    ..were diagnosed (with separate exploration of the two most common regimens at the time, cyclophosphamide/methotrexate/5-FU and Adriamycin/ cyclophosphamide) Depending on findings, results from this application will support future ..
  38. A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT
    Joseph H Antin; Fiscal Year: 2013
    ..Bortezomib in combination with tacrolimus and methotrexate (tac/mtx/bort) has been shown to be useful in preventing GVHD in a phase l/ll trial...
  39. Gene Expression in Pediatric Arthritis
    Susan D Thompson; Fiscal Year: 2013
    ..Cell Signature" expressed in many older polyarticular JIA patients appears to predict inadequate responses to methotrexate, and it is also associated with increased expression of putative JIA susceptibility loci...
  40. PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children
    Mary V Relling; Fiscal Year: 2013
    ..pharmacogenomics, pharmacokinetics (cellular and plasma), antileukemic and toxic effects of glucocorticoids, methotrexate, thiopurines, asparaginase, anthracyclines, and vincristine. The approach is summarized in four major Steps...
  41. Drosophila as a model for chemotherapy pharmacogenomics
    ANTHONY DOUGLAS LONG; Fiscal Year: 2012
    ..g., X-ray or EMS). The initial drug we will examine is Methotrexate because of wide clinical use to treat cancer and arthritis, known toxicities, and conservation of target ..
  42. Targeting the relief of chronic pain with orally active peroxynitrite decompositi
    Daniela Salvemini; Fiscal Year: 2010
    ..manner with subtherapeutic levels of selective COXII inhibitors, non-selective COX-I inhibitors, steroids, and methotrexate. Thus, through this approach we may be able to greatly lower the dosages of these important drugs for effective ..
  43. Molecular Mechanism of miR-140 in Colon Cancer
    Jingfang Ju; Fiscal Year: 2013
    ..As a result, these cells became more resistant to 5-fluorouracil (5-FU) or methotrexate (MTX) treatment...
  44. Effect of low dose methotrexate on endothelial function and inflammation in HIV
    James H Stein; Fiscal Year: 2013
    ..Low-dose methotrexate (LDMTX) is a safe treatment for patients with rheumatoid arthritis that appears to reduce CVD risk...
  45. Human Folylpolyglutamate Synthetase and Cancer Therapeutics
    Richard G Moran; Fiscal Year: 2013
    ..the human enzyme and the effects of such feedback on the pharmacology of the antifolates used in cancer, namely methotrexate, raltitredid and pemetrexed. The enzymology related to this putative feedback will also be explored...
  46. 99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis
    John A Zebala; Fiscal Year: 2011
    ..A major paradigm shift in diagnostic and therapeutic approach is therefore required. Methotrexate (MTX) is the drug of first choice in treating RA, however, it fails to achieve clinical remission in about 80% ..
  47. Anticancer Drug Pharmacology in Very Young Children
    Clinton F Stewart; Fiscal Year: 2013
    ..Thus, we propose to perform clinical pharmacokinetic (PK), pharmacogenetic, and pharmacodynamic (PD) studies of methotrexate (MTX), cyclophosphamide (CTX), and topotecan (TPT) as part of a clinical protocol that treats infants and young ..
  48. Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis
    John A Zebala; Fiscal Year: 2010
    ..At the conclusion of the Phase 2 and 3 clinical trials proposed herein, we aim to have the necessary efficacy and safety data required for a Product License Application (NDA,) to the FDA for the use of AMT in psoriasis. ..
  49. Early Aggressive Therapy in Juvenile Idiopathic Arthritis
    Carol Wallace; Fiscal Year: 2009
    ..2-17 years with poly-JIA of recent onset will be randomized to 1 of 2 aggressive treatment regimens: Arm A = Methotrexate (MTX;0...
  50. Curcuma longa L. in Rheumatoid Arthritis (CLaRA): Clinical Planning Study
    Janet L Funk; Fiscal Year: 2013
    ..administering curcuminoids to biologic naive RA patients with active disease who have inadequately responded to methotrexate, including pharmacokinetic studies and estimates of effect size on known inflammatory biomarkers...
  51. Novel Risk Factors For Vancomycin Resistant Enterococci In Persons With Cancer
    Mini Kamboj; Fiscal Year: 2013
    ..the effect of commonly used chemotherapeutic agents with strong antimicrobial activity, (5-Fluorouracil and Methotrexate) upon density of VRE among colonized individuals...
  52. Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes
    THOMAS PATRICK LOUGHRAN; Fiscal Year: 2012
    ..designed to deliver cell-permeable analogs of ceramide (C6 ceramide) as well as target-specific siRNA and/or Methotrexate, will be tested in a Fischer F344 rat model of LGL leukemia...
  53. MOLECULAR REGULATION OF FOLATE AND ANTIFOLATE TRANSPORT
    Larry H Matherly; Fiscal Year: 2013
    ..Antifolates, represented by methotrexate and, more recently, raltitrexed and pemetrexed, continue to occupy a unique and important niche among the ..
  54. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
    Nisha Acharya; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The goal of this study is to establish which immuno-suppressive therapy - methotrexate or mycophenolate mofetil - is more effective as a first-line, corticosteroid-sparing agent for the treatment of ..
  55. Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
    S Louis Bridges; Fiscal Year: 2010
    ..effective in every patient, and there is great variability in toxicity and price, ranging from ~$400/year for methotrexate (MTX) to up to $15,000/year for biologic agents...
  56. MEthotrexate Response in Treatment of UC - MERIT-UC
    Hans H Herfarth; Fiscal Year: 2013
    ..4) To establish a DNA, plasma and serum library to enable the evaluation of clinical and pharmacogenomic models to predict the response to MTX therapy in patients with UC. ..
  57. Molecular Analyses of Folate and Antifolate Transport
    Charles E Dann; Fiscal Year: 2013
    ..A prime example is the classic antifolate methotrexate (MTX), which is still commonly used at low doses in treatment of cancer, psoriasis and arthritic disease...
  58. Mechanisms of Immune Modulation in JIA
    NORA SINGER; Fiscal Year: 2013
    ..The central hypothesis for this project is that effective therapies with methotrexate (MTX) alone or in combination with Etanercept (ETN) and prednisolone induce inactive disease (ID) in ..
  59. The Treatment of Methotrexate Resistant Rheumatoid Arthritis With Aminopterin
    Stuart Kahn; Fiscal Year: 2009
    ..b>Methotrexate (MTX), an antifolate used alone or in combination with other medicines, is the current mainstay and reference ..
  60. PENETRATION OF MACROMOLEULCES INTO CELLS
    H Ryser; Fiscal Year: 1999
    ..proteolytically undegradable polymer (poly(D-lysine)), through disulfide linkage either to an anticancer drug (methotrexate) to obtain a cytocidal conjugate (MTX-SS-PDL) or to 125I-tyramine to obtain a labeled analogue (125I-tyn-SS-PDL)..
  61. Protein Dynamics in Dihydrofolate Reductase Catalysis
    PETER EDWIN WRIGHT; Fiscal Year: 2013
    ..DHFR is the target for anti-folate drugs such as the anticancer agent methotrexate and the antibacterials trimethoprim and iclaprim...
  62. URSODIOL-METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS
    Burton Combes; Fiscal Year: 2003
    ..treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone...
  63. Ethnic Differences in Survival after Childhood ALL
    Smita Bhatia; Fiscal Year: 2009
    ..phase of approximately two years composed of oral administration of antimetabolites [6-Mercaptopurine (6MP) and methotrexate (MTX)] in order to achieve durable remissions...
  64. METHOTREXATE EFFECTS OF ASTROCYTES
    Jocelyn Bruce; Fiscal Year: 1992
    Clinicopathologic and experimental data suggest that astrocytes may be the most likely target for methotrexate (MTX) toxicity in the central nervous system (CNS)...
  65. MOLECULAR CORRELATES OF METHOTREXATE IN CHILDHOOD ALL
    Larry Matherly; Fiscal Year: 2007
    ..The focus is on methotrexate (MTX) and 6-mercaptopurine (6-MP), antimetabolites that continue to be cornerstones of modern treatment ..
  66. TUMOR MARKERS TO PREDICT TREATMENT RESPONSE
    Lynn Dressler; Fiscal Year: 2005
    ..by the CALGB, entitled," A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil- "CMF" or Cyclophosphamide and Doxorubicin -"AC" versus Capecitabine in Women 65 Years and ..
  67. DRUG RESISTANCE AND GENE AMPLIFICATION IN LEISHMANIA
    Stephen Beverley; Fiscal Year: 2002
    ..will focus on the role of these genes in resistance to the clinically-utilized pentavalent antimonials; 2) the methotrexate resistance gene hmtx(r), which encodes a protein exhibiting substantial homology to a large family of ..
  68. Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis
    Stuart Kahn; Fiscal Year: 2009
    ..Other systemic immunosuppressive medications, including methotrexate, are being investigated, but an effective, safe treatment for these patients has yet to be defined...